X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57) 57
index medicus (49) 49
oncology (38) 38
male (35) 35
adult (30) 30
female (30) 30
middle aged (30) 30
hematology (28) 28
aged (24) 24
cancer (22) 22
chemotherapy (18) 18
stem cells (12) 12
transplantation (12) 12
apoptosis (11) 11
medical colleges (11) 11
adolescent (10) 10
leukemia (10) 10
care and treatment (9) 9
medicine & public health (9) 9
patients (9) 9
treatment outcome (9) 9
young adult (9) 9
acute myeloid leukemia (8) 8
analysis (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
prognosis (8) 8
aged, 80 and over (7) 7
hematopoietic stem cells (7) 7
medicine, general & internal (7) 7
research (7) 7
taiwan (7) 7
animals (6) 6
bone marrow (6) 6
cell line, tumor (6) 6
disease-free survival (6) 6
genes (6) 6
immunology (6) 6
medical research (6) 6
mesenchymal stromal cells - cytology (6) 6
neoplasm staging (6) 6
neutropenia (6) 6
stem cell transplantation (6) 6
abridged index medicus (5) 5
apoptosis - drug effects (5) 5
cell biology (5) 5
cells (5) 5
complications (5) 5
expression (5) 5
gene expression (5) 5
hematology, oncology and palliative medicine (5) 5
hematopoietic stem cell transplantation (5) 5
lymphocytes t (5) 5
lymphomas (5) 5
macromolecular substances (5) 5
medicine (5) 5
mesenchymal stromal cells - metabolism (5) 5
multidisciplinary sciences (5) 5
prevention (5) 5
reactive oxygen species - metabolism (5) 5
risk factors (5) 5
studies (5) 5
therapy (5) 5
transcription factors - metabolism (5) 5
adjuvant chemotherapy (4) 4
bone-marrow-transplantation (4) 4
child (4) 4
clinical trials (4) 4
cytogenetics (4) 4
deferasirox (4) 4
diagnosis, differential (4) 4
differentiation (4) 4
double-blind method (4) 4
doxorubicin (4) 4
enhancer of zeste homolog 2 protein (4) 4
ezh2 (4) 4
high-dose chemotherapy (4) 4
hospitals (4) 4
infection (4) 4
infections (4) 4
internal medicine (4) 4
leukemia, myeloid, acute - drug therapy (4) 4
lymphoma (4) 4
medical prognosis (4) 4
metastases (4) 4
metastasis (4) 4
mice (4) 4
mortality (4) 4
myelodysplastic syndrome (4) 4
myelodysplastic syndromes - drug therapy (4) 4
myeloid leukemia (4) 4
nasopharyngeal carcinoma (4) 4
open-label (4) 4
phosphorylation (4) 4
prospective studies (4) 4
quality of life (4) 4
randomization (4) 4
safety (4) 4
science (4) 4
survival (4) 4
time factors (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0197851
Journal Article
Nature Cell Biology, ISSN 1465-7392, 01/2011, Volume 13, Issue 1, pp. 87 - 94
Journal Article
STEM CELLS, ISSN 1066-5099, 08/2016, Volume 34, Issue 8, pp. 2183 - 2193
Journal Article
Annals of Hematology, ISSN 0939-5555, 10/2019, Volume 98, Issue 10, pp. 2447 - 2450
Journal Article
Scientific Reports, ISSN 2045-2322, 08/2016, Volume 6, Issue 1, p. 32428
Mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 in acute myeloid leukemia (AML) cells produce the oncometabolite R-2-hydroxyglutarate (R-2HG) to induce... 
AML | LOCATION | PROGENITORS | IDH2 MUTATIONS | INHIBITION | BONE-MARROW STROMA | MUTANT IDH2 | MULTIDISCIPLINARY SCIENCES | LEUKEMOGENESIS | DIFFERENTIATION | 2-HYDROXYGLUTARATE | Interleukin-8 - genetics | NIMA-Interacting Peptidylprolyl Isomerase - metabolism | Phosphorylation | Reactive Oxygen Species - metabolism | Humans | Leukemia, Myeloid, Acute - metabolism | Complement C5a - metabolism | NF-kappa B - metabolism | Mitogen-Activated Protein Kinase 1 - genetics | Myeloid Cells - drug effects | Receptors, CXCR4 - genetics | Interleukin-8 - metabolism | Protein Stability | Interleukin-6 - metabolism | Mesenchymal Stromal Cells - drug effects | Interleukin-6 - genetics | Junctional Adhesion Molecule B - metabolism | Mitogen-Activated Protein Kinase 3 - genetics | Signal Transduction | Leukemia, Myeloid, Acute - pathology | Paracrine Communication - genetics | Mesenchymal Stromal Cells - metabolism | Isocitrate Dehydrogenase - genetics | Gene Expression Regulation, Leukemic | NIMA-Interacting Peptidylprolyl Isomerase - genetics | Receptors, CXCR4 - metabolism | Junctional Adhesion Molecule B - genetics | Mitogen-Activated Protein Kinase 3 - metabolism | NF-kappa B - genetics | Paracrine Communication - drug effects | Myeloid Cells - metabolism | Complement C5a - genetics | Isocitrate Dehydrogenase - metabolism | Glutarates - metabolism | Glutarates - pharmacology | Mesenchymal Stromal Cells - pathology | Mutation | Myeloid Cells - pathology | Primary Cell Culture | Leukemia, Myeloid, Acute - genetics | Mitogen-Activated Protein Kinase 1 - metabolism | Cell proliferation | NF-κB protein | Reactive oxygen species | Peptidylprolyl isomerase | Transcription | Myeloid leukemia | Leukemia | Extracellular signal-regulated kinase | Paracrine signalling | Pin1 protein | CXCR4 protein | Hemopoiesis | Interleukin 6 | Chemotherapy | Stromal cells | Bone marrow | Isocitrate dehydrogenase | Acute myeloid leukemia | Interleukin 8 | Apoptosis
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 04/2013, Volume 5, Issue 4, pp. 531 - 547
EZH2 plays an important role in stem cell renewal and maintenance by inducing gene silencing via its histone methyltransferase activity. Previously, we showed... 
Smurf2 | human mesenchymal stem cells (hMSCs) | ischaemic neuronal injury | neuron differentiation | EZH2 | Ischaemic neuronal injury | Human mesenchymal stem cells (hMSCs) | Neuron differentiation | MEDICINE, RESEARCH & EXPERIMENTAL | DEVELOPMENTAL REGULATORS | MOUSE DEVELOPMENT | HISTONE H3 | EMBRYONIC STEM-CELLS | ADULT BONE-MARROW | RAT-BRAIN | CEREBRAL-ISCHEMIA | UP-REGULATION | MARROW STROMAL CELLS | E3 UBIQUITIN LIGASE | Up-Regulation | Polycomb Repressive Complex 2 - genetics | Humans | Ubiquitin-Protein Ligases - metabolism | Rats | Male | Neurons - cytology | Neurogenesis | Rats, Sprague-Dawley | Stroke - physiopathology | Enhancer of Zeste Homolog 2 Protein | Stroke - genetics | Stroke - metabolism | Animals | Proteolysis | Neurons - metabolism | Polycomb Repressive Complex 2 - metabolism | Ubiquitin-Protein Ligases - genetics | Ubiquitin | Medical colleges | Care and treatment | Nervous system diseases | Neurons | Genes | Transferases | Stroke (Disease) | DNA microarrays | Ischemia | Ligases | Stem cells | Histones | Genetic engineering | Cancer | Animal models | Spinal cord | Mesenchyme | Recovery of function | Stem cell transplantation | Nervous system | Kinases | Experiments | Proteins | Allografts | Bone marrow | Histone methyltransferase | Ubiquitin-protein ligase | Medical research | Stroke | Statistical analysis | Neurodegenerative diseases | Therapeutic applications | Cell differentiation | Gene expression | Gene silencing | Brain research | MicroRNAs | Rosiglitazone
Journal Article
by Horwitz, Steven and O'Connor, Owen A and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Advani, Ranjana and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Bartlett, Nancy and Belada, David and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fanale, Michelle and Fay, Keith and Feldman, Tatyana and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Christensen, Jacob Haaber and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Horwitz, Steven and Huttmann, Andreas and Illes, Arpad and Illidge, Tim and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and ... and ECHELON-2 Study Group and ECHELON 2 Study Grp
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Journal Article
by Petrylak, Daniel P and de Wit, Ronald and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor J and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Chi, Kim Nguyen and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Laestadius, Fredrik and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Bamias, Aristotelis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Peer, Avivit and Sarid, David and Scagliotti, Giorgio Vittorio and Sternberg, Cora N and Tortora, Giampaolo and Bracarda, Sergio and Necchi, Andrea and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Matsubara, Nobuaki and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and ... and RANGE study investigators and RANGE Study Investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | MEDICINE, GENERAL & INTERNAL | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | COMBINATION | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis
Journal Article
Cancer Medicine, ISSN 2045-7634, 02/2017, Volume 6, Issue 2, pp. 349 - 360
Journal Article